We are live on ! Find out more
TRAW icon

Traws Pharma
TRAW

56 hedge funds and large institutions have $33.6M invested in Traws Pharma in 2021 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 15 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

460% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 5

392% more capital invested

Capital invested by funds: $6.83M → $33.6M (+$26.8M)

200% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 5

70% more funds holding

Funds holding: 33 → 56 (+23)

0.02% more ownership

Funds ownership: 0.02% → 0.04% (+0.02%)

Holders
56
Holders Change
+23
Holders Change %
+69.7%
% of All Funds
0.98%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
28
Increased
15
Reduced
5
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$3.72M
2
BlackRock
BlackRock
New York
+$3.62M
3
Millennium Management
Millennium Management
New York
+$2.84M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$2.29M
5
CH
CVI Holdings
Delaware
+$1.32M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$514K
2
GCP
GSA Capital Partners
United Kingdom
-$106K
3
TRCT
Tower Research Capital (TRC)
New York
-$61.9K
4
BPA
Beacon Pointe Advisors
California
-$38.9K
5
MA
MONECO Advisors
Connecticut
-$30.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
State Street
26
State Street
Massachusetts
$93K +$93.5K +248 New
QP
27
Quilter Plc
United Kingdom
$81K +$13.2K +35 +19%
Capstone Investment Advisors
28
Capstone Investment Advisors
New York
$71K +$71.3K +189 New
Barclays
29
Barclays
United Kingdom
$65K +$64.1K +170 +5,667%
MC
30
Moors & Cabot
Massachusetts
$65K +$65.3K +173 New
Citadel Advisors
31
Citadel Advisors
Florida
$58K -$514K -1,362 -90%
UBS Group
32
UBS Group
Switzerland
$58K -$754 -2 -1%
CANY
33
Caxton Associates (New York)
New York
$57K +$57.3K +152 New
TRCT
34
Tower Research Capital (TRC)
New York
$48K -$61.9K -164 -56%
FWP
35
FAS Wealth Partners
Kansas
$38K – – –
RJA
36
Raymond James & Associates
Florida
$38K – – –
Victory Capital Management
37
Victory Capital Management
Texas
$36K +$5.28K +14 +17%
Voloridge Investment Management
38
Voloridge Investment Management
Florida
$36K +$36.6K +97 New
MA
39
MONECO Advisors
Connecticut
$30K -$30.2K -80 -50%
SWMP
40
Signature Wealth Management Partners
New Jersey
$26K +$754 +2 +3%
9WM
41
9258 Wealth Management
Ohio
$16K – – –
ARTA
42
A.R.T. Advisors
New York
$16K +$16.6K +44 New
SSA
43
Schonfeld Strategic Advisors
New York
$14K +$13.6K +36 New
RFM
44
Royal Fund Management
Florida
$14K +$15.1K +40 New
CAN
45
Cetera Advisor Networks
California
$13K +$13.2K +35 New
Cambridge Investment Research Advisors
46
Cambridge Investment Research Advisors
Iowa
$11K – – –
BW
47
Bison Wealth
Georgia
$10K +$10.6K +28 New
Rockefeller Capital Management
48
Rockefeller Capital Management
New York
$8K – – –
SWM
49
Spire Wealth Management
Virginia
$5K +$4.53K +12 New
Wells Fargo
50
Wells Fargo
California
$2K +$377 +1 +33%
1
2
3

TRAW Hedge Fund Activity: Q1 2021 in Review

56 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q1 2021, worth a combined $33.6M — up 392% from $6.83M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new TRAW positions and 5 closed out — a net gain of 23 holders — while 15 added to existing stakes and 5 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $3.72M. The largest seller was Citadel Advisors, cutting an estimated $514K.

  • 56 institutional investors held Traws Pharma (TRAW) as of Q1 2021, up from 33 in Q4 2020.
  • Funds reported $33.6M of Traws Pharma stock for Q1 2021, up 392% quarter-over-quarter.
  • 28 funds opened new Traws Pharma positions in Q1 2021 and 5 closed out, a net change of +23 holders.
  • The largest Traws Pharma buyer in Q1 2021 was Renaissance Technologies, an estimated $3.72M added.
  • The largest Traws Pharma seller in Q1 2021 was Citadel Advisors, an estimated $514K sold.

Based on aggregated 13F filings for Q1 2021.